Search Share Prices
Diurnal secures Japanese patents and aims for further international commercialisation
Specialty pharmaceutical company Diurnal has secured two Japanese composition of matter patents for new products, it announced on Thursday.
The patents are for Diurnal's Alkindi product, a treatment for adrenal insufficiency in paediatric and elderly adult patients now protected until 2032, and its Chronocort product, giving the company's modified release hydrocortisone formulation in market protection until 2033.
Martin Whitaker, chief executive of Diurnal, said: "Japan is a significant potential market for both Alkindi and Chronocort. We are therefore delighted that these patents have proceeded to grant and will create the cornerstone of our strong exclusivity position in this territory."
The company's UK and US variants of the patents have already been granted.
"We will now look to secure a local partner, in line with our commercialisation strategy outside of the US and Europe, and will liaise with local regulatory authorities to determine the clinical studies that will be required for approval," said Whitaker.
Diurnal is a Cardiff-based company, dedicated to auctioning high-quality hormone therapeutics to assist with lifelong treatment for rare and chronic endocrine conditions such as congenital adrenal hyperplasia, hypothyroidism and adrenal insufficiency.
As of 0848 GMT, Diurnal shares were up 1.69% at 180.50p.